Synaptogenix Inc (SNPX)

[runncoach]

bryostatin is a PKC modulator. Short term exposure promotes PKC activation whereas prolonged exposure results in significant down regulation. That was the reason for the "exploratory" trial as there is a sweet spot that they needed to be found. The 40 ug arm actually gave an initial dose of 50 followed by a second dose of 50 one week later according to company slides. It was simply too much. Then you have memantine interfering with the reaction and you likely have a drug that is "trying to work" but between down regulation and memeantine blocking what the drug is trying to do, you end up with unpredictable efficacy on top of worse side effects and more people dropping out. I'm just not sure how much can be gleaned from that data when you have clean 20 ug data to set up this year's trial. JMHO